Skip to main content
Contact Us
Subscribe
E-Edition
73°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Renovaro Inc. - Common Stock
(NQ:
RENB
)
0.6340
+0.0703 (+12.47%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Renovaro Inc. - Common Stock
< Previous
1
2
3
4
Next >
Renovaro Issues Shareholder Letter and Provides Corporate Update
November 04, 2024
From
Renovaro Inc
Via
GlobeNewswire
RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing
October 17, 2024
From
Renovaro Inc
Via
GlobeNewswire
Powerful Leadership Transition to Optimize Highly Promising AI Platform, RenovaroCube for Multi-Cancer Early Detection and Patient Monitoring: Renovaro, Inc. (Nasdaq: RENB)
October 16, 2024
Via
Get News
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Renovaro Announces Strategic Restructuring and Leadership Transition
October 16, 2024
From
Renovaro Inc
Via
GlobeNewswire
PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics
September 19, 2024
Strategic partnership aims to further develop Cube’s award-winning AI guided platform for Software as a Service (SaaS) for the private sector and large healthcare systems and diagnostic to support...
From
Renovaro Inc
Via
GlobeNewswire
Specialist AI Team from “PersonalAIze” Highlights the Strength, Potential and Visionary Talent Behind Software as a Service (SaaS) Platform for Early Cancer Detection: Renovaro, Inc. (Nasdaq: RENB)
September 17, 2024
Via
Get News
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
September 17, 2024
Assessment by specialist AI team from “PersonalAIze” Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform
From
Renovaro Inc
Via
GlobeNewswire
RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
September 13, 2024
From
Renovaro Inc
Via
GlobeNewswire
RenovaroCube Announces Strategic Offering of Up to 20% Ownership
September 11, 2024
From
Renovaro Inc
Via
GlobeNewswire
Renovaro, Inc. Announces $10 million in Equity Committed
June 14, 2024
From
Renovaro Inc
Via
GlobeNewswire
Impressive Short Squeeze Triggered for Cancer Immunotherapy Company Renovaro, Inc. (NASDAQ: RENB)
June 10, 2024
Via
Get News
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy
May 24, 2024
From
Renovaro Inc
Via
GlobeNewswire
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
May 24, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:RENB),(NASDAQ:CYTO),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Launch of Groundbreaking Cancer Detection Platform Flamingo with Nvidia AI Computing Power, Plus Plans to Acquire 100% Ownership of Cyclomics: Renovaro Inc. (Nasdaq: RENB)
April 30, 2024
Via
Get News
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
May 24, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
April 30, 2024
From
Renovaro Inc
Via
GlobeNewswire
Trailblazing AI Driven Early Cancer Diagnostics and Therapeutics for Detection with Nvidia Super Computing Power; Acquiring 100% Ownership of Cyclomics; Renovaro Inc. (Nasdaq: RENB)
April 25, 2024
Via
Get News
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership
April 24, 2024
From
Renovaro Inc
Via
GlobeNewswire
Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient
April 18, 2024
From
Renovaro Biosciences Inc.
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Chemours, Trupanion, and Renovaro and Encourages Investors to Contact the Firm
March 04, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Renovaro Biosciences Inc. Investors to Inquire About Securities Class Action Investigation - RENB
February 27, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Renovaro Biosciences Inc. Investors to Inquire About Securities Class Action Investigation - RENB
February 27, 2024
WHY: NEW YORK, NY - (NewMediaWire) - February 27, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Renovaro...
Via
TheNewswire.com
ROSEN, A TOP RANKED LAW FIRM, Encourages Renovaro Biosciences Inc. Investors to Inquire About Securities Class Action Investigation – RENB
February 24, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
RENOVARO ALERT: Bragar Eagel & Squire, P.C. is Investigating Renovaro Biosciences Inc. on Behalf of Renovaro Stockholders and Encourages Investors to Contact the Firm
February 20, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Renovaro Biosciences Inc. Investors to Inquire About Securities Class Action Investigation - RENB
February 20, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
ROSEN, A LEADING LAW FIRM, Encourages Renovaro Biosciences Inc. Investors to Inquire About Securities Class Action Investigation - RENB
February 20, 2024
WHY: NEW YORK, NY - (NewMediaWire) - February 20, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Renovaro...
Via
TheNewswire.com
RENB SHAREHOLDER ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Renovaro Biosciences Inc. Investors to Inquire About Securities Class Action Investigation – RENB
February 19, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Cutting Edge Blood Genetic Testing Using Nvidia AI Chips Emerging from Acquisition of Dutch Based Cyclomics; Aim to Disrupt Cancer Diagnosis and Treatment: Renovaro Biosciences Inc. (Nasdaq: RENB)
February 16, 2024
Via
Get News
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
February 15, 2024
From
Renovaro Biosciences Inc.
Via
GlobeNewswire
Statement of Renovaro Inc
February 14, 2024
From
Renovaro Biosciences Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.